The European Medicines Agency (EMA) endorses TRICALS’ innovative platform trial

TRICALS has received the exciting news that the European Medicines Agency (EMA)…

Words Lucie van Leeuwen.Published July 23, 2020
The European Medicines Agency (EMA) endorses TRICALS’ innovative platform trial

TRICALS has received the exciting news that the European Medicines Agency (EMA) endorses our plans for an innovative platform trial. Clinical trials investigating candidate medicines for ALS are costly, lengthy and often inaccessible for the majority of patients. This complicates and delays our search for effective treatments. By endorsing our state-of-the-art study protocol, the EMA allows us to radically improve current clinical trial design for ALS.

The key objectives of TRICALS are to accelerate the development of new treatments for ALS and to make clinical trials accessible for all patients. The support of the EMA for our platform trial design is therefore an important milestone. With our clinical platform trial, coined the ‘MAGNET’ study, we will be able to test multiple treatments simultaneously. Using computer models we can furthermore drastically increase the percentage of people with ALS that can participate in clinical trials (up to at least 75-85% of all patients).

Our proposal to use our time more efficiently during clinical trials has also been endorsed by the EMA. This means we will be quicker to start new clinical trials and to complete studies once we have acquired enough conclusive evidence about the efficacy of an experimental therapy. As a result, this will reduce the duration that patients are exposed to ineffective medicines. Importantly, we can get successful therapies to other patients more rapidly. Click here to read more about the MAGNET trial.

The positive review by the EMA opens the door to innovate and speed up clinical trials throughout our international network. The MAGNET study is now also likely to attract pharmaceutical interest from all over the world to initiate new clinical trials in Europe. Overall, the MAGNET study will prove an important landmark on our highway towards new therapies for ALS.


Share

Related news

New centres in Portugal and Spain join TRICALS network
New centres in Portugal and Spain join TRICALS network
We are very excited to announce that recently two new expert ALS […]
Towards remote muscle strength measurements using a newly developed portable fixed dynamometer
Towards remote muscle strength measurements using a newly developed portable fixed dynamometer
Progressive muscle weakness is the hallmark of ALS. Evaluating muscle strength is […]
Newsletter December 2020
Newsletter December 2020
2020 has been a difficult year for everyone. However, despite the many […]
Reconsidering the ALSFRS-R for ALS clinical trials
Reconsidering the ALSFRS-R for ALS clinical trials
Questionnaires, such as the ALS Functional Rating Scale (ALSFRS), play an important […]